Hospira sued for patent infringement over allergic injections
Florida-based company Belcher Pharmaceuticals has filed a complaint against Hospira for patent infringement.
The case was filed on Friday, June 16, at the US District Court for the District of Delaware.
Belcher alleged that Hospira intends to market a generic epinephrine injection USP called Abboject.
The injection is used for emergency treatments of allergic reactions.
According to Belcher, Hospira’s plans to bring the injection to market infringe its US patent number 9,283,197, titled “More potent and less toxic formulations of epinephrine and methods of medical use”.
Belcher has asked the court for costs for bringing the case to court.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk